ГоловнаArchive of numbers2018Volume 26, issue 3 (96)Clinical, pharmacological and economic advantages related to treatment of acute and chronic pain syndrome
Title of the article Clinical, pharmacological and economic advantages related to treatment of acute and chronic pain syndrome
Authors Golovach Iryna
Year 2018 Issue Volume 26, issue 3 (96) Pages 77-82
Type of article Scientific article Index UDK [615.275.3:615.015.11+615.038]:616-009.7:616-036.11+616.036.12 Index BBK -
Abstract The article presents the advantages of clinical use of naproxen in acute and chronic pain syndrome. Today, naproxen is considered as a drug of choice in the treatment of patients with existing cardiovascular risk. The administration of naproxen in combination with proton pump inhibitors has been recognized as the most appropriate approach for relieving pain in patients with a combination of moderate/high cardiovascular risk and a moderate risk of gastrointestinal complications. The clinical and pharmacological advantages of using naproxen in various clinical situations are examined
Key words nonsteroidal anti-infl ammatory drugs, pain, naproxen, cardiovascular risk
Access to full text version of the article pdf download
Bibliography 1. Головач И. Ю. Стратеги чес кие решения в отношении безопасности и возможности длительной терапии нестероид- ными противовоспалительными препаратами при остеоартри- те // Травма. 2017. Т. 18, № 4. С. 27—34. DOI: 10.22141/1608- 1706.4.18.2017.109341. 2. Головач І. Ю. Ефективність та доцільність застосування напроксену при різних клінічних ситуаціях // Укр. неврол. журнал. 2017; 8(94): 65—70. DOI: 10.22141/2224-0713.8.94.2017.120703. 3. Дані національної аналітичної системи «Моріон», компанії «ProximaResearch», за період січень — травень 2018, станом на липень 2018 р. 4. Каратеев А. Е. Количественная и качественная оценка риска осложнений при использовании нестероидных противовоспали- тельных препаратов как основа формирования рекомендаций по их конт ро лю и профилактике // Современная ревматология. 2014; 8 (1): 64—72. DOI: 10.14412/1996-7012-2014-1-64-72. 5. Клини чес кие рекомендации «Рациональное применение не- стероидных противовоспалительных препаратов (НПВП) в клини- чес кой практике» / Каратеев А. Е., Насонов Е. Л., Яхно Н. Н. [и др.] // Там же. 2015; 9 (1): 4—24. DOI: 10.14412/1996-7012-2015-1-4-23. 6. Муравьев Ю. В. Почему исследование комплексной без- опасности целекоксиба при артритах, названное РRECISION, является последним по счету, а не по значимости? // Научно- практ. ревматология. 2017; 55 (3): 324—326. DOI: 10.14412/1995- 4484-2017-324-326 7. Олюнин Ю. А. Применение нестероидных противовоспали- тельных препаратов у больных с высоким кардиоваскулярным риском // Там же. 2017; 5 (3): 321—323. DOI: 10.14412/1995-4484- 2017-321-323. 8. Рачина С. А., Андреева А. С., Беденков А. В. ATC/DDD ме- тодология: основные принципы и практи чес кое использование в исследованиях потребления лекарственных средств // Клини- чес кая фармакология и терапия. 2002; 11: 44—48. 9. Чеберда А. Е. Исследования потребления лекарственных средств // Качественная клини чес кая практика. 2017; 1: 42—45. 10. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis / Bombardier C., Laine L., Reicin A. [et al.] // N. Engl. J. Med. 2000; 343(21): 1520—1528. DOI: 10.1056/NEJM200011233432103. 11. The appropriate use of non-steroidal antiinflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel / Burmester G., Lanas A., Biasucci L. [et al.] // Ann Rheum Dis. 2011; 70(5): 818—22. DOI: 10.1136/ard.2010. 128660. 12. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects / Capone M. L., Tacconelli S., Sciulli M. G. [et al.] // Circulation. 2004; 109: 1468—1471. DOI: 10.1161/01. CIR.0000124715.27937.78. 13. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project) / Castellsague J., Riera-Guardia N., Calingaert B. [et al.] // Drug Saf. 2012; 35: 1127—1146. DOI: 10.2165/11633470- 000000000-00000.14. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis / Collantes E., Curtis S. P., Lee K. W. [et al.] // BMC Fam. Pract. 2002; 3: 10. 15. Conaghan P. G. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity // Rheumatol. Int. 2012; 32(6): 1491—1502. DOI: 10.1007/s00296-011-2263-6. 16. Cook R. J., Sackett D. L. The number needed to treat: a clinically userul measure of treatment effect // BMJ. 1995; 310: 452—454. 17. Derry C., Derry S., Moore R. A., McQuay H. J. Single dose oral naproxen and naproxen sodium for acute postoperative pain in adults // Cochrane Database Syst Rev. 2009; 1: CD00423. DOI: 10.1002/14651858.CD004234.pub3. 18. European Medicines Agency concludes review of systemic nimesulide-containing medicines. Use to be restricted to treatment of acute pain and primary dysmenorrhoea. 23/06/2011. URL : http:// www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/ news/2011/06/news_detail_001285.jsp&mid=WC0b01ac058004d5c1. 19. Fanella A., Ghisi D., Aprile P. L., Lapi F. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclo oxygenase 2 inhibitors: latest evidence and clinical impli ca tions // Ther Adv Drug Saf. 2017; 8(6): 173—182. DOI: 10.1177/2042098617690485. 20. Fine M. Quantifying the impact of NSAID-associated adverse events // Am J Manag Care. 2013; 19 (14 Suppl): 267—272. 21. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland / Helin-Salmivaara A., Virtanen A., Vesalainen R. [et al.] // Eur. Heart J. 2006; 27: 1657—1663. DOI: 10.1093/eurheartj/ehl053. 22. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis / Henry D., Lim L. L., Garcia Rodriguez L. A. [et al.] // BMJ. 1996; 312: 1563—1566. 23. Henry D., McGettigan P. Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs // Int J Clin Pract. 2003; 135: 43—49. 24. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population / Huerta C., Castellsague J., Varas-Loren zo C. [et al.] // Am J Kidney Dis. 2005; 45(3): 531—539. DOI: 10.1053/j. ajkd.2004.12.005. 25. Structural correlates of pain in joints with osteoarthritis / Hunter D. J., Guermazi A., Roemer F. [et al.] // Osteoarthritis Cartilage. 2013; 21(9): 1170—1178. DOI: 10.1016/j.joca.2013.05.017. 26. Laine L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors // Semin. Arthritis Rheum. 2002; 32(3 Suppl 1): 25—32. DOI: 10.1053/sarh.2002.37217 27. Lee Y. Effect and treatment of chronic pain in inflammatory arthritis // Curr Rheum Rep. 2013; 15(1): 300. DOI: 10.1007/ s11926-012-0300-4. 28. Leung G. J., Rainsford K. D., Kean W. F. Osteoarthritis of the hand II: chemistry, pharmacokinetics and pharmacodynamics of naproxen, and clinical outcome studies // J Pharm Pharmacol. 2014; 66(3): 347—357. URL : https: //doi. org/10.1111/jphp.12165. 29. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study / MacDonald T. M., Morant S. V., Robinson G. C. [et al.] // BMJ. 1997; 315: 1333—1337. 30. Masso Gonzalez E. L., Patrignani P., Tacconelli S., Garcia Rodriguez L. A. Variability among non steroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding // Arthritis Rheum. 2010; 62: 1592—1601. DOI: 10.1002/art.27412. 31. McQuay H., Moore A. Using numerical results from systematic reviews in clinical practice // Ann. Internal Med. 1997; 126: 712—720. 32. Moore R. A., Derry S., Aldington D., Wiffen P. J. Single dose oral analgesics for acute postoperative pain in adults — an overview of Cochrane reviews // Cochrane Database of Systematic Reviews. 2015. Issue 9. Art. No.: CD008659. DOI: 10.1002/14651858. CD008659.pub3. 33. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis / Nissen S. E., Yeomans N. D., Soloman D. H. [et al.] // N Engl. J. Med. 2016; 375(26): 2519—2529. DOI: 10.1056/NEJMoa1611593. 34. Ong C. K. S., Lirk P., Tan C. H., Seymour R. A. An Evidence- Based Update on Nonsteroidal Anti-Inflammatory Drugs // Clin Med Res. 2007; 5(1): 19—34. DOI: 10.3121/cmr.2007.698. 35. Managing the adverse effects of nonsteroidal antiinflammatory drugs / Patrignani P., Tacconelli S., Bruno A. [et al.] // Expert Rev Clin Pharmacol. 2011; 4: 605—621. DOI: 10.1586/ecp.11.36. 36. Pelletier J.-P., Martel-Pelletier J., Rannou F., Cooper C. Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys // Semin Arthritis Rheum. 2016; 45: S22—S27. DOI: 10.1016/j. semarthrit.2015.11.009. 37. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis / Reginster J., Malmstrom K., Mehta A. [et al.] // Ann. Rheum. Dis. 2007; 66(7): 945—951. DOI: 10.1136/ard.2006.059162 38. Schiff M., Hochberg M. C., Oldenhof J., Brune K. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin // Curr Med Res Opin. 2009; 25(10): 2471—2477. DOI: 10.1185/03007990903185706. 39. Naproxen sodium and paracetamol/dextropropoxyphene in sports injuries — a multicentre comparative study / Simmons R. L., Owen S., Abbott C. J. [et al.] // Br J Sports Med. 1982; 16(2): 91—95. URL : https: //doi.org/10.1136/bjsm.16.2.91. 40. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study / Singh G., Fort J., Goldstein J. [et al.] // Am. J. Med. 2006; 119(3): 255—266. DOI: 10.1016/j.amjmed.2005.09.054 41. Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis: A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal / Song G., Seo Y., Kim J. [et al.] // J. Rheumatol. 2016; 75(5): 508—516. DOI: 10.1007/s00393-015-0023-9. 42. Cardiovascular safety of non-steroidal antiinflammatory drugs: network meta-analysis / Trelle S., Reichenbach S., Wandel S. [et al.] // BMJ. 2011; 342: 7086. DOI: 10.1136/ bmj.c7086. 43. Pain Treatment in Arthritis-Related Pain: Beyond NSAIDs / Van der Laar M., Pergolizzi J., Mellinghoff H. [et al.] // Open Rheum J. 2012; 6: 320—330. 44. Wongrakpanich S., Wongrakpanich A., Melhado K., Rangaswami J. A. Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly // Aging Dis. 2018; 9(1): 143—150. DOI: 10.14336/AD.2017.0306.